DIAKONOS RESEARCH LTD.
The Diakonos Promise
Let’s be blunt –cancer treatments are horrible. By and large, we’re using the same barbaric techniques that were invented almost 100 years ago. And even with some of the remarkable advancements of the past 40 years, many cancers continue to maintain a pretty dismal prognosis and cancer treatment still seems stuck in the Dark Ages.
But there’s even worse news. Many of our peers – the physicians, scientists, lawyers, businessmen, and government officials we have tasked with curing cancer – many of these people have given up. They don’t believe that cancer will ever realistically be cured and they settle. And why not? Sometimes it seems so hopeless. It’s only human nature.
But Diakonos is different. We haven’t settled. We haven’t given up. Not now, not yet, not ever. Not today and definitely not tomorrow. We continue to devote our careers and lives to the pursuit of sound, scientific achievement. Diakonos has made critical discoveries regarding the way the immune system works and how it can effectively be used to target - and eliminate - cancer. We’ve taken the time, energy, and resources to get to know the entire immune system - to understand how all the different parts work together to produce the whole. If that sounds hard and expensive, well, it was – we’ve been at this a long time. But the results have been nothing short of spectacular. Today we are positioned at the leading edge of immuno-oncology and are poised to reap the benefits of a lifetime of patience and hard work.
Where biology leads, we follow. That’s the Diakonos Promise.
A NEW GENERATION OF IMMUNOTHERAPY
Effective Cancer Immunotherapy
The immune system in general and dendritic cells in particular have long been touted as the vehicles by which cancer will be treated in a targeted and gentle fashion, sparing patients from the debilitating side-effects and frequent treatment failures of cytotoxic cancer therapy. Unfortunately, despite enormous advances made in the understanding of basic immunology, vaccine immunotherapy has yet to produce reasonable therapeutic results for any indication. Cancer vaccines have yet to perform as advertised in a clinical setting.
Diakonos Research Ltd (Diakonos) is changing this perception of vaccine immunotherapy. Diakonos scientists have been focused on the reasons why dendritic cell immunotherapy has not worked in the past, paying particular attention to the overlooked concepts of T-cell homing and stimulation of a certain critical immune cell subset- the plasmacytoid dendritic cell. More importantly, we have discovered and characterized a “missing signal” that tells the immune system to generate the kinds of immune responses necessary to fight cancer. Stimulation of the immune system in this fashion produces a response robust and specific enough to control physiologic cancers in large animal models. Since the existence of this signal was unknown until recently, previous immunotherapy treatment protocols did not take advantage of it and unlikely stimulated the immune system to function optimally with any reasonable frequency. By applying a radically different understanding of the way that immune responses are generated, we are able to formulate cutting-edge treatments that produce results. Patent applications covering critical elements of the treatment protocol have been filed in conjunction with Baylor College of Medicine.